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SUMMARY 
 Microcephaly has been defined as an occipitofrontal head circumference of equal 
to or less than 2-3 standard deviations below the mean related for age and gender. It may 
develop prenatally (congenital microcephaly) or postnatally and may have genetic or non-
genetic causes. Although a wide spectrum of genetic defects can result in microcephaly, 
traditionally a group of microcephalies has been distinguished as autosomal recessive 
primary microcephaly (MicroCephaly Primary Hereditary, MCPH).     
Both megalencephaly and macrocephaly have been defined as conditions with 
head circumference that exceeds the mean by 2 or more standard deviations (SD) for age 
and gender. Megalencephaly refers to an enlarged brain due to increased growth of 
cerebral structures during brain development, while in macrocephaly the enlarged head is 
the result of hydrocephalus, subdural fluid collections or intracranial masses. 
Megalencephaly can be idiopathic, or can be associated with metabolic disorders, or 
genetic syndromes.  
Objectives 
The aims of this study were to characterize the phenotypic and genotypic features 
of three patients with autosomal recessive primary microcephaly and two children with 
megalencephaly.  
Methods 
 Thorough assessment of the patients has been carried out including physical and 
neurological examination and developmental testing. Chromosomal analysis and array 
comparative genome hybridization (aCGH) were performed, followed by next generation 
sequencing. Whole exome sequencing (WES) was performed for three patients with 
autosomal recessive primary microcephaly (ASPM and WDR62 genes, CentoXome® at 
Centogene AG, Rostock, Germany). The Illumina Trusight One Exome Sequencing Panel 
(Illumina Inc., San Diego, California, USA) was used for the analysis of mutations in two 
genes (FOXP1 and PTCH1) in a girl with megalencephaly (Department of Paediatrics, 
University of Szeged). Multiplex targeted sequencing was applied using single molecule 
molecular inversion probes in the patient with megalencephaly and AKT3 mutation (in 
collaboration with scientists in the USA). The mutations were confirmed by Sanger 
sequencing.  
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Patients and Results 
Patient 1./ A novel homozygous nonsense variant in the ASPM gene [c.7323T>A, 
p.(Tyr2441Ter)] in exon 18 in a boy was associated with congenital microcephaly, severe 
developmental delay and MRI features of cortical dysplasia and polymicrogyria.   
Patients 2 and 3./ A boy and a girl had the same novel homozygous missense 
variant [c.668T>C, p.(Phe223Ser)] in exon 6 in the WDR62 gene. They had 
hemispherical asymmetry and diffuse pachygyria on the MRI in addition to microcephaly 
and severe developmental delay, Haplotype analysis suggested close relationship between 
the families of these patients.    
Patient 4./ A girl with extreme megalencephaly and profound intellectual 
disability had de novo heterozygous variants in exon 18 of the FOXP1  
[c.1573C>T, p.(Arg525Ter)] gene and exon 17 of the PTCH1 
[c.2834delGinsAGATGTTGTGGACCC, p.(Arg945GlnfsTer22)] gene. The PTCH1 
mutation was novel. 
Patient 5./ Megalencephaly, diffuse polymicrogyria and delayed development 
were the characteristic features of a boy with an activating de novo germline 
heterozygous missense variant [c.1393C>T; p.(Arg465Trp)] in exon 13 of the AKT3 
gene, which encodes a member of the PI3K (phosphatidylinositol-3-kinase)–AKT (AK 
mouse + Transforming or Thymoma)-mTOR) pathway. 
Conclusions 
Rare autosomal recessive primary microcephaly (MCPH) due to mutations in 
ASPM and WDR62 might be the result of abnormal function of the centrosomes, which 
organize the separation of chromosome copies during cell division. Megalencephaly in 
association with pathogenic mutations in two genes (FOXP1 and PTCH1) in the same 
individual is exceptionally rare and the severe phenotype might have been the result of 
the combined effect of this genetic constellation.  Activating mutation in a gene (AKT3) 
encoding a member of the PI3K-AKT-mTOR pathway in association with 
megalencephaly is also a rare condition. It is justified therefore, to devote this study to the 
thorough work up of these patients; it is in line with the international endeavour to 
identify the genetic causes of rare diseases by applying new technologies, particularly 
array methods and next generation sequencing. 
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ÖSSZEFOGLALÁS 
 Microcephaliában a fejkörfogat kisebb, mint az életkorra és nemre jellemző 2 
standard deviáció (SD). Microcephalia kialakulhat prenatalisan (congenitalis 
microcephalia), vagy postnatalisan, mindkét esetben az etiológia lehet genetikai 
rendellenesség, vagy környezeti ártalom. Bár rendkívül sokféle genetikai defektus 
okozhat microcephaliát, a szakirodalom megkülönbözteti az autoszomális recesszív 
primer  microcephaliák (MicroCephaly Primary Hereditary, MCPH) csoportját.    
Megalencephalia és macrocephalia esetén a fejkörfogat meghaladja az életkorra 
és nemre vonatkoztatott 2 standard deviációt (SD). Megalencephalia az agyi struktúrák 
fokozott növekedésére utal, mig macrocephaliáról beszélünk hydrocephalus, subduralis 
folyadékgyülem, vagy egyéb intracranialis térszűkítő folyamat esetén. A megalencephalia 
lehet idiopathiás, veleszületett anyagcsere betegség következménye, vagy társulhat 
genetikai szindrómákhoz.  
Célkitűzések 
 Átnézve a SZTE Gyermekklinika B Részlegének Neurológiai Szakrendelésén 
vizsgált betegek adatait, 3 beteget találtunk, akik ritka autoszomális recesszív primer 
microcephaliában szenvedtek, 2 beteget pedig megalencephaliával azonosítottunk. Célul 
tűztük ki az 5 beteg fenotípusának és genotípusának az elemzését.  
Módszerek 
 Fizikális és neurológiai vizsgálat történt, továbbá a fejlődést is értékeltük. 
Kromoszóma vizsgálat és array összehasonlító genomiális hibridizáció után új generációs 
szekvenálás következett. A három, microcephaliában szenvedő beteg mutációját az ASPM 
és WDR62 génben teljes exom szekvenálás (WES) derítette ki (CentoXome®) a 
Centogene Laboratóriumban, Németországban. Az Illumina Trusight One Exome 
Sequencing Panel (Illumina Inc., San Diego, California, USA) alkalmazásával sikerült 
megtalálni a mutációt két génben (FOXP1 és PTCH1) az SZTE Gyermekgyógyászati 
Klinikán egy megalencephaliában szenvedő leányban. Egy fiúban pedig többszörös 
célzott szekvenálással (multiplex targeted sequencing using single molecular inversion 
probes) derült ki mutáció az AKT3 génben, mint a megalencephalia oka az Amerikai 
Egyesült Államokban.  Sanger szekvenálással megerősítettük a mutációkat.    
Betegek és eredmények 
 1. beteg. Az ASPM gén egy új, eddig nem közölt homozigóta mutációja [exon 18: 
c.7323T>A, p.(Tyr2441Ter)] okozott súlyos congenitalis microcephaliát, corticalis 
dysplasiát és polymicrogyriát egy fiúban, akinek a fejlődése súlyosan késlekedett.  
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 2-3. beteg. A WDR62 gén új és azonos homozigóta mutációja [exon 6: c.668T>C, 
p.(Phe223Ser)] derült ki egy fiúban és egy leányban, akik súlyos congenitalis 
microcephaliában szenvedtek. Fejlődésük súlyosan késlekedett, az MRI pedig az agyi 
féltekék aszimmetriáját és pachygyriát mutatott. A haplotípus analízis rokonságot 
valószínűsített a betegek családjai között.       
4. beteg. Egy leányban de novo heterozigóta patogén mutációt találtunk a FOXP1 
[exon 18: c.1573C>T, p.(Arg525Ter)] és a PTCH1 [exon 17: 
c.2834delGinsAGATGTTGTGGACCC, p.(Arg945GlnfsTer22) génben. A PTCH1 
mutáció új, még nem közölt variáns.  
5. beteg. Egy fiúban, akinek késlekedett a fejlődése, diffúz polymicrogyria társult 
a megalencephaliához. A molekuláris vizsgálat során de novo germline heterozigóta 
missense mutáció [exon 13: c.1393C>T; p.´(Arg465Trp)] igazolódott az AKT3 génben. 
Következtetések 
 Az ASPM és WDR62 gének által kódolt fehérjék szükségesek a centrosomák 
normális funkciójához. Ezek az organellumok fontos szerepet játszanak a 
sejtosztódásban, és kóros működésük autoszomális recesszív primer microcephaliát 
eredményez. Megalencephalia két gén (FOXP1 és PTCH1) patogén mutációjának 
következtében egy betegben rendkívül ritka. A kifejezett megalencephalia és a súlyos 
értelmi fogyatékosság a két mutáció együttes hatásának lehetett a következménye. 
Megalencephalia a PI3K-AKT-mTOR jelátviteli rendszer egyik elemét kódoló gén 
(AKT3) aktiváló mutációja következtében szintén ritka. Betegeink tanulmányozása és 
eredményeink disszertációba foglalása összhangban van azokkal a nemzetközi 
törekvésekkel, amelyek az új genetikai technológiák alkalmazásával kutatják a ritka 
betegségek okait.     
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INTRODUCTION 
Microcephaly has been defined as an occipitofrontal head circumference of equal 
to or less than 2-3 standard deviations (SD) below the mean related for age and gender 
(Zaqout et al., 2017, Jayaraman et al., 2018). Microcephaly may develop prenatally 
(congenital microcephaly) or postnatally and may have genetic or non-genetic causes. 
Any condition that affects important processes of brain growth, including progenitor cell 
proliferation, cell differentiation, and cell death, can lead to microcephaly (von der Hagen 
et al., 2014, Zaqout et al., 2017). Anomalies causing microcephaly may exclusively affect 
cerebral development (non-syndromic microcephaly) or may be associated with 
dysmorphic features and extracerebral malformations (syndromic microcephaly) (von der 
Hagen et al., 2014). The spectrum of phenotypes and associated disorders of 
“microcephaly” is wide with 1429 entries recorded to September 2019 in The Online 
Mendelian Inheritance in Man (OMIM) database. 
Although a wide spectrum of genetic defects can result in microcephaly, 
traditionally a group of microcephalies is distinguished as autosomal recessive primary 
microcephaly (MicroCephaly Primary Hereditary, MCPH) (Zaqout et al., 2017). At least 
18 genetic loci (MCPH1-18 until September 2019) have been implicated in MCPH, all of 
which have now been connected to single genes: MCPH1, WDR62, CDK5RAP2, CASC5, 
ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6, 
MFSD2A, ANKLE2, CIT, WDFY3 (Jayaraman et al., 2018). Many of the proteins encoded 
by these genes interact with the centrosomes, which organizes the separation of 
chromosome copies during cell division. The architecture of the small brain with 
simplified gyral pattern was not grossly affected in patients described initially, subsequent 
studies, however, revealed a wide spectrum of cortical malformations in association with 
MCPH of different aetiologies, particularly WDR62 mutations (Jayaraman et al., 2018, 
Shohayeb et al., 2018).     
 We report on three patients who had autosomal recessive primary microcephaly in 
association with abnormal cortical architecture: a boy with a novel nonsense mutation in 
the ASPM gene (OMIM 605481; abnormal spindle-like, microcephaly-associated protein, 
MicroCephaly Primary Hereditary 5, chromosome 1q31.3) and two other patients, a boy 
and a girl with the same novel missense mutations in WDR62 (OMIM 613583; WD repeat 
containing protein 62, MicroCephaly Primary Hereditary 2, chromosome 19q13.12). 
 Megalencephaly and macrocephaly have been defined as conditions with head 
circumference above the age-related mean by 2 or more standard deviations. 
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Megalencephaly defines an increased growth of cerebral structures because of either 
increased size or number of neurons and glial cells. In contrast, in macrocephaly, the 
increased head circumference is linked to hydrocephalus, subdural fluid collections, or 
intracranial masses (Mirzaa and Poduri, 2014, Pavone et al., 2017).  
Megalencephaly can be idiopathic/benign or it can be associated with metabolic 
disorders, or genetic syndromes.  
Idiopathic/benign megalencephaly refers to children who have an abnormally 
large head with no neurological impairment. An increased head circumference is often 
reported in one or both the parents as well. 
In metabolic megalencephaly, the clinical course is usually progressive with a 
more or less rapid neurological impairment. Defects in the organic acid metabolism, like 
glutaric aciduria type 1, or L-2-hydroxyglutaric aciduria are associated with 
megalencephaly. Several forms of leukoencephalopathies, such as Canavan disease, 
Alexander disease, megalencephalic leukoencephalopathy with subcortical cysts can 
cause megalencephaly. Accumulation of metabolic substrates is also accompanied with 
megalencephaly in lysosomal storage disorders, such as Tay-Sachs disease, Sandhoff 
disease, or mucopolysaccharidoses (Mirzaa and Poduri, 2014, Pavone et al., 2017). 
Megalencephaly is a phenotypic feature of Sotos, Weaver, Simpson-Golabi-
Behmal, PTEN hamartoma tumour and Gorlin syndromes among others. Recently, 
megalencephaly as a presenting sign has been reported in megalencephaly-
polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome. Mostly de novo germline 
or somatic mutations in PIK3R2 (chromosome 19p13.11) and AKT3 (chromosome 1q43-
q44) have been found in this disorder. These genes encode members of the PI3K-AKT-
mTOR pathway (Mirzaa and Poduri, 2014, Pavone et al., 2017). 
The phenotypic features and molecular genetic findings of two patients with 
megalencephaly are presented in this study. A girl with extreme megalencephaly and 
profound intellectual disability had de novo mutations in two genes, such as FOXP1 
(forkhead box protein P1; OMIM 605515, chromosome 3p13) and PTCH1 (patched 
homolog 1, OMIM 601309, chromosome 9q22.3). Megalencephaly, diffuse 
polymicrogyria and delayed development were the characteristic features of a boy with a 
germline de novo mutation in AKT3 (AK mouse + Transforming or Thymoma, OMIM 
611223, chromosome 1q43-q44). 
Autosomal recessive primary microcephaly due to ASPM or WDR62 mutations are 
rare conditions. Megalencephaly in association with pathogenic mutations in two genes 
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(FOXP1 and PTCH1) in the same individual and activating mutation in a member of the 
PI3K-AKT-mTOR pathway is also very rare. It is justified therefore to devote this study 
to the thorough work up of these patients. It is in line with the international endeavour to 
identify the genetic causes of rare diseases by applying new technologies, particularly 
array methods and next generation sequencing.  
 
OBJECTIVES 
The aims of this study were  
1./ to ascertain patients with rare forms of autosomal recessive primary microcephaly and 
megalencephaly 
2./ to assess these patients, including physical and neurological examination and 
developmental testing 
3./ to evaluate the brain MR images 
4./ to identify the molecular genetic causes of these conditions  
 
METHODS 
Patients with autosomal recessive primary microcephaly (3 children) and 
megalencephaly (2 children) were enrolled out of the patient population referred to the 
Paediatric Neurology Service (outpatient and inpatient), Department of Paediatrics, 
Division B, University of Szeged, Hungary between 1 January 2006 and 31 December 
2017.  
Standard assessment included clinical history of the antenatal, perinatal, neonatal, 
and postnatal period. Physical and neurological examinations were carried out. Special 
attention has been paid to the presence of dysmorphic features and malformations. A 
standardized vocabulary of phenotypic abnormalities, provided by the Human Phenotype 
Ontology has been applied. Hearing was always tested and neuro-ophthalmologic 
consultation was also an integral part of the examinations. The developmental milestones, 
cognitive and behavioural phenotypes were also assessed. Screening for inborn errors of 
metabolism and intrauterine infections were carried out by conventional methods. Brain 
MRI was performed in axial, coronal and sagittal planes.      
Routine chromosomal analysis occurred by G-banding. Genomic DNA was 
isolated from the peripheral blood in all patients and also from saliva in Patient 5. Array 
comparative genomic hybridization was performed using the Affymetrix 750K array. 
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In Patients 1-3 whole exome sequencing (WES trio) was performed with 
CentoXome
®
 at Centogene AG (Rostock, Germany). Genomic capture was carried out 
with Illumina’s Nextera Rapid Capture Exome Kit. Massively parallel sequencing was 
done using NextSeq500 Sequencer (Illumina) in combination with the NextSeq™ 500 
High Output Kit (2x150bp). Raw sequence data analysis, including base calling, de-
multiplexing, alignment to the hg19 human reference genome (Genome Reference 
Consortium GRCh37), and variant calling, were performed using an in house 
bioinformatics pipeline. For variant filtration, all disease-causing variants reported in 
Human Gene Mutation Database (HGMD®), ClinVar or in CentoMD® as well as all 
variants with minor allele frequency (MAF) of less than 1% in Exome Aggregation 
Consortium (ExAc) database were considered. Variants that possibly impair the protein 
sequence, i.e. disruption of conserved splice sites, missense, nonsense, read-throughs, or 
small insertions/deletions, were prioritized. All relevant inheritance patterns were 
considered.  
In Patient 4 the Illumina Trusight One Exome Sequencing Panel (Illumina Inc., 
San Diego, CA, USA), covering the coding region of 4,813 clinically relevant genes, was 
applied using Illumina MiSeq (Illumina Inc., San Diego, California, USA). Variants were 
filtered based on severity and frequency against public variant databases including single-
nucleotide polymorphism database (dbSNP), ClinVar, ExAC, Exome Variant Server 
(EVS) and in-house clinical exome database of 140 unrelated Hungarian persons. All 
relevant inheritance patterns were considered.  
In Patient 5 multiplex targeted sequencing was applied using single molecule 
molecular inversion probes (smMIP, Hiatt et al., 2013, Alcantara et al., 2017).  
All candidate pathogenic variants were confirmed by conventional PCR 
amplification and Sanger sequencing. Segregation of these changes with the disease was 
assessed for all available family members. 
Haplotype analysis of the families   
Since the families of Patients 2-3 with the same WDR62 mutation were unaware 
of any relation between them, we performed a haplotype analysis to investigate their 
potential genetic relation. Plink (version v1.90b4.9) was used to convert variants in the 
region of interest to Pedigree (PED) and MAP files from the joint Variant Call Format 
(VCF) file (Chang et al., 2015). Haplotype analysis was performed by Merlin (version 
1.1.2.) software with the “--best” option using the PED, Data (DAT), and MAP files 
prepared manually from the plink output files (Abecasis et al., 2002). HaploPainter 
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(version 1.043) was used to visualize the haplotypes in the families (Thiele and Nürnberg, 
2005).  
An informed consent to participate in this study was requested from the parents. 
This study was approved by the Human Investigation Review Board, University of 
Szeged, Albert Szent-Györgyi Clinical Center (3797/2016.  
 
PATIENTS AND RESULTS (Table 1) 
MICROCEPHALY (PATIENTS 1-3) 
Patient 1 - ASPM mutation  
This boy was born from the first pregnancy to unrelated healthy parents at 36
th
 
gestational week. Apgar scores were 9 and 10 at 1 and 5 minutes, respectively. His birth 
weight was 2350 g (-0.9 SD), length 47 cm (-0.1 SD). Microcephaly was noted at birth 
with head circumference of ~30 cm (-1.8 SD). The pregnancy was complicated by 
threatened abortion, however there were no report of infection, alcohol use or substance 
abuse. The microcephaly progressed with head circumference of 39 cm (-5.1 SD) at 10 
months, 40,5 cm (-5.2 SD) at 18 months, and 43.5 cm (-5.7 SD) at 5,5 years of age. His 
weight was 18 kg (-0.4 SD) and height 110 cm (-0.7 SD) at this age. Sloping forehead and 
disproportionately large face and ears as compared to the skull were observed. Motor and 
intellectual development was severely impaired with inability to sit and stand 
unsupported or speak at the age of 5 years. He followed objects and responded to loud 
sounds. Typical signs of spastic tetraplegia (spastic quadriplegia) were observed. Tonic-
clonic seizures appeared at the age of 18 months and the interictal EEG showed bilateral 
symmetric and asymmetric spike and wave discharges. The seizures were well controlled 
with valproate. 
Brain MRI at age of 7 months showed an abnormal cortical pattern with features 
of cortical dysplasia and polymicrogyria. The grey-white matter junction appeared 
indistinct at some areas. The Virchow-Robin spaces and lateral ventricles were dilated 
(Fig. 1. A, B, C).  
The WES trio (Centogene AG) identified a novel homozygous pathogenic variant, 
c.7323T>A, p.(Tyr2441Ter) in exon 18 of the ASPM gene in the patient (Fig. 2). This 
variant creates a premature stop codon and it is consistent with the diagnosis of autosomal 
recessive primary microcephaly type 5. The detected variant was also found in 
heterozygous state in the patient’s parents.  To date this variant has not been described in 
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the Exome Aggregation Consortium, Exome Sequencing Project or the 1000 Genome 
Browser.  
Patient 2 – WDR62 mutation 
This boy was born at term from the third pregnancy with Cesarean section to 
healthy consanguineous parents of Romani ethnicity (Fig. 3 A). Apgar scores were 8 and 
8 at 1 and 5 minutes, respectively. Severe microcephaly was noted at birth with head 
circumference of 30 cm (-3.5 SD). The birthweight was 2900 g (-1.0 SD) and length 50 
cm (0.1 SD). The pregnancy was unremarkable, with no report of infection, alcohol use or 
substance abuse. The parents have a healthy son and a healthy daughter. Microcephaly 
progressed, with head circumference of 40 cm (-6.0 SD) at 2 years and 41.5 cm (-6.0 SD) 
at 4 years of age. The patient also had failure to thrive with a height of 89 cm (-3.4 SD) 
and a weight of 12 kg (-2.4 SD) at 4 years of age. Sloping forehead and 
disproportionately large face and ears as compared to the skull were observed. He 
followed objects and responded to loud sounds. His motor and intellectual development 
was severely impaired with inability to sit and stand unsupported, or reach out for objects 
at the age of 5 years. He had no words, but showed emotions. Global hypotonia was 
present with preserved deep tendon reflexes. Infantile spasms began at 4 months of age 
and were well controlled with vigabatrin, which was tapered off and discontinued by 3 
years of age. One year later complex partial seizures appeared and the EEG showed 
interictal short paroxysms of bilateral spike and wave discharges. Valproate treatment 
was initiated and proved to be successful. 
 MRI at age of 5 months showed hemispherical asymmetry (R>L) and abnormal 
cortical pattern. Diffuse pachygyria was observed with a few broad gyri, thick grey matter 
and shallow sulci (Fig. 4 A, B).   
Patient 3 – WDR62 mutation  
This girl was born at term from the first pregnancy with Cesarean section because 
of fetal bradycardia to healthy parents of Romani ethnicity. They denied consanguinity 
(Fig. 3 B).  Apgar scores were 7, 9 and 10 at 1, 5 and 10 minutes, respectively. The 
pregnancy was complicated with urinary tract infection. Severe microcephaly was noted 
at birth with head circumference of 28 cm (-5.0 SD). Her birthweight was 2490 g (-0.4 
SD) and length 46 cm (-1.7 SD). There was no evidence of intrauterine infection, alcohol 
use or substance abuse. Microcephaly progressed, with head circumference of 39 cm (-5.9 
SD) at 2 years and 40 cm (-6.6 SD) at 4 years of age. The patient also had signs of failure 
to thrive with height of 88 cm (-3.4 SD) and weight of 12,4 kg (-2.0 SD) at 4 years of age. 
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On examination at the age of 14 months she had severe convergent squint, but followed 
objects and responded to loud sounds. Her motor and cognitive development was severely 
lagged behind with inability to sit, stand or reach out for objects. There was a moderate 
decrease in the muscle tone with slight left sided weakness and preserved deep tendon 
reflexes. No further development was observed until the last follow up at 5 years of age. 
Complex partial seizures started after 3 years of age and the interictal EEG showed 
bilateral spike and wave discharges. The epilepsy was well controlled with valproate 
treatment.  
 MRI at the age of 4 years showed hemispherical asymmetry (L>R) and abnormal 
cortical pattern similar to Patient 2 (Fig. 4, C, D).  
 WES trio (Centogene AG) identified the same novel homozygous missense 
variant, c.668T>C, p.(Phe223Ser) in exon 6 in the WDR62 gene in Patients 2 and 3. The 
detected variant was also found in heterozygous state in the patients’ parents and the 
brother of Patient 2 (Fig. 3. A, B, C). To date this variant has not been described in the 
Exome Aggregation Consortium, Exome Sequencing Project or the 1000 Genome 
Browser. It is located in a highly conserved nucleotide (phyloP: 4.48) with large 
physicochemical differences between the exchanged amino acids Phenylalanine and 
Serine (Alamut v.2.7.1). Prediction programs Polyphen2, SIFT and MutationTaster 
predicted pathogenicity of the variant which affects the WD40 repeat region of the 
protein (Fig. 3. D), whereas Align-GVGD predicted toleration.  
The family members of Patients 2 and 3 were unaware of any relatedness. 
Haplotype analysis showed that both families carry exactly the same haplotype for the 
entire WDR62 gene (around 55 kilobases) as shown in Fig. 5. Our results, therefore, 
suggest that the two families are closely related genetically.   
 
MEGALENCEPHALY (PATIENTS 4-5) 
Patient 4 – Coexistence of FOXP1 and PTCH1 mutation 
The proband, a girl was born as the second child to healthy, non-consanguineous 
parents at 36 weeks of gestation via vaginal delivery with birth weight of 2,870 g (0.4 
SD), length of 50 cm (0.8 SD) and head circumference of 37 cm (1.8 SD). Apgar scores 
were 8, 9 and 10 at 1, 5 and 10 minutes, respectively. There was no evidence of 
intrauterine infection or inborn error of metabolism.  
Several dysmorphic features were noticed (Fig. 6 A, B, D). Progressive growth of 
her head circumference was noted; it was 58 cm (6.1 SD) at the age of 4 years, and 61 cm 
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(7.1 SD) at the age of 8 years (Fig. 6 C). Her height was 129 cm (0.2 SD) and weight 33 
kg (1.3 SD) at 8 years of age. On examination, her hearing proved to be normal. She 
required glasses because of severe myopia. Generalized hypotonia, unstable gait and 
preserved deep tendon reflexes were observed. Her motor and cognitive development was 
severely delayed with inability to speak or follow commands at the age of 8 years. 
Brunet-Lézine test at the age of 2.5 years showed a developmental quotient of 40. She 
had temporary outbursts of aggressive behaviour. 
Brain MRI, performed at 3 months, 3 and 4 years of age revealed partial agenesis 
of the corpus callosum and widely separated leaves of the septum pellucidum (Fig, 6 E, 
F). Brain CT was not performed. Abdominal and cardiac ultrasound, chest X-ray and 
dental radiography were normal.  
Chromosomal analysis showed a normal 46,XX karyotype. Copy number changes 
were not found by Affymetrix 750K array. Clinical exome (Trusight One panel) 
sequencing revealed heterozygous variants in exon 18 of the FOXP1 [c.1573C>T, 
p.(Arg525Ter)] and exon 17 of the PTCH1 [c.2834delGinsAGATGTTGTGGACCC, 
p.(Arg945GlnfsTer22)] genes in the patient (Figs. 7, 8). The FOXP1 variant has been 
reported earlier as a nonsense pathogen mutation (rs112795301, RCV000005214), while 
the PTCH1 variant has not been found in either dbSNP, ClinVar, ExAC, or EVS 
databases or a cohort of 140 unrelated Hungarian controls. Sanger sequencing confirmed 
both variants as de novo mutations in the patient. They were not present either in the 
parents or in the patient’s healthy brother (Figs. 7, 8).  
Patient 5 - AKT3 mutation 
 The patient, a boy was born by Cesarean section from the second uneventful 
pregnancy at 36
th
 gestational weeks to unrelated healthy Caucasian parents. His 
birthweight was 3280g (1.3 SD), length 50 cm (1.2 SD) and head circumference 37.5 cm 
(3.3 SD). There was no history of alcohol use or substance abuse and there was no 
evidence of intrauterine infection or inborn error of metabolism. The infant did not have 
hypoglycaemia. He had a healthy brother.  
 His head circumference was 51 cm (5.1 SD) at 7 months of corrected age, 53 cm 
(4.5 SD) at 15 months and 55 cm (4.1 SD) at 28 months of age. His weight was 11.5 kg (-
1.3 SD) and height 82 cm (-2.2 SD) at this age. Dysmorphic features, such as bossing 
forehead, wide nasal bridge, short nose and bilateral partial cutaneous syndactyly of III-
IV toes were observed. At the age of 3 years, his vision and hearing were normal, 
however, he had severe chewing impairment and did not speak. Connective tissue laxity, 
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muscular hypoplasia, generalized hypotonia and weakness were noticed. The deep tendon 
reflexes were preserved. He was able to stand and make a few steps. Recurrent tonic-
clonic seizures with and without fever appeared after the age of 11 months. They were 
well controlled with levetiracetam and an EEG at the age of 2.5 years did not show 
epileptiform discharges.  
MRI was performed at 7 months of age and it revealed polymicrogyria in the 
perisylvian, frontal, parietal and temporal areas on both sides (Fig. 9). 
Chromosomal analysis showed a normal 46,XY karyotype. Targeted next 
generation sequencing (Alcantara et al., 2017) revealed a heterozygous missense variant 
[c.1393C>T, p.(Arg465Trp)] in exon 13 of the AKT3 gene (Fig. 10 A,B). This pathogenic 
variant was present in 50% of reads in the DNA samples derived from both the blood and 
saliva, suggesting a constitutional mutation. The mutation was confirmed by Sanger 
sequencing. It was a de novo mutation, absent in the parental samples. 
 
DISCUSSION 
MICROCEPHALY 
Proliferation of the neural progenitor cells 
Brain size at birth is primarily dependent on the ability of neural progenitor cells 
(neuroepithelial cells, radial glia cells and short neural precursors with apical-basal 
polarity lining the ventricles of the foetal brain) to proliferate and self-renew. While 
symmetrical division of a neural progenitor cell results in the generation of two identical 
neural progenitor cells (thereby increasing the progenitor pool), asymmetrical division 
leads to the production of one progenitor cell (thereby maintaining the progenitor pool) 
and a committed precursor, which eventually undergoes migration and differentiates into 
neuron (Dehay and Kennedy, 2007, Fish et al., 2008, Uzquiano et al., 2018; Explanatory 
figure 1, 2). 
The cell cycle of eukaryotic cells can be divided into four successive phases: M 
phase (mitosis), S phase (DNA synthesis) and two gap phases, G1 and G2. Centrosomes 
play an essential role in cell division, as they are responsible for the formation and 
maintenance of the microtubule-based spindle apparatus. The centrosome contains a pair 
of cylindrical centrioles in an orthogonal configuration. The centrioles are surrounded by 
pericentriolar matrix of proteins and centrosomal satellites. The satellites are granular 
structures implicated in the trafficking of material involved in centriole assembly. 
Centriole duplication occurs during each cell-cycle and both centrioles and centrosomes 
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undergo final maturation in the G2 and M phases (Prosser and Pelletier, 2017, Nigg and 
Holland, 2018, Explanatory figure 3/A). Centrosome duplication in dividing 
neuroprogenitors generates a pair of centrosomes with differently aged mother centrioles. 
During peak phases of neurogenesis the centrosome retaining the old mother centriole 
stays in the ventricular zone and is preferentially inherited by neuroprogenitors, whereas 
the centrosome containing the new mother centriole mostly leaves the ventricular zone 
and is largely associated with differentiating cells (Wang et al., 2009, Explanatory figure 
3/C).    
Centrosomal duplication results in the generation of a bipolar mitotic spindle 
(Explanatory figure 3/B). The chromosomes attach to bundles of microtubules via 
kinetochores, which are multiprotein complexes that assemble on the centromere of each 
sister chromatid (Prosser and Pelletier, 2017). The mitotic processes are dependent also 
upon the highly conserved Chromosomal Passenger Complex, consisting of Aurora B 
kinase, INner CENtromere Protein (INCENP), Survivin and Borealin. Aurora B is the 
enzymatically active member of the complex. INCENP functions as a scaffolding protein, 
while Survivin and Borealin are targeting subunits. This complex targets to different 
locations at differing times during mitosis, where it regulates key mitotic events, such as 
correction of kinetochore-microtubule attachment errors, activation of the spindle 
assembly checkpoint, and construction and regulation of the contractile apparatus that 
drives cytokinesis (Carmena et al., 2012).  
ASPM and WDR62 encode centrosomal proteins functioning in the division of neural 
progenitor cells (Explanatory figure 4) 
 ASPM (OMIM 605481; abnormal spindle-like, microcephaly-associated protein) 
mutations cause MCPH5 (MicroCephaly Primary Hereditary 5), while WDR62 (OMIM 
613583; WD repeat containing protein 62) mutations are responsible for MCPH2. These 
are the most common causes of autosomal recessive primary microcephaly (Zaqout et al., 
2017). ASPM maps at 1q31.3 locus. The full-length ASPM gene contains 28 exons and 
encodes a spindle pole associated protein consisting of 3477 amino-acids, although 
alternatively spliced variants have also been detected (Kouprina et al., 2005, Létard et al, 
2018). The main ASPM isoform contains an amino-terminal ASH (ASPM, SPD-2, 
Hydin) domain with a putative microtubule-binding function, an actin binding domain 
comprising two calponin homology (CH) domains, an IQ domain consisting of a series of 
repeated calmodulin-binding IQ (isoleucine-glutamine) motifs of variable length, an 
Armadillo-like domain, and a carboxyl-terminal region. This protein is conserved 
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between Drosophila, worm, mouse and human, with a consistent correlation of nervous 
system complexity and protein length, principally involving an increase in the number of 
calmodulin binding IQ motifs; the human protein displays 81 IQ motifs at positions 1273 
to 3234. Calmodulin appears to regulate protein function by modulating its ability to bind 
to different targets either by altering the conformation of the protein or by influencing its 
subcellular location (Kouprina et al, 2005, Létard et al., 2018). More than 200 mutations, 
mostly nonsense or frameshift mutations, randomly distributed over the gene have been 
published so far. No genotype-phenotype correlation has been found (Létard et al., 2018).  
 The homozygous nonsense ASPM mutation [c.7323T>A, p.(Tyr2441Ter)] in exon 
18, which creates a premature stop codon within the IQ domain (at repeat 49) in our 
patient has not been published yet. It may result either in unstable mRNA that would be 
degraded by nonsense–mediated RNA decay, or truncation of the protein at the 
calmodulin-binding IQ repeats domain. We did not perform functional studies to verify 
any of these mechanisms. Anyway, earlier studies on patients with ASPM mutations 
revealed the presence of truncated proteins indicating that the mutated ASPM mRNAs 
were not sensitive to nonsense-mediated RNA decay (Kouprina et al., 2005, Higgins et 
al., 2010). Majority of patients with ASPM mutations exhibit cerebral manifestations, but 
the somatic growth remains unaffected. It has been postulated, that either a functional 
compensatory mechanism exists in the somatic cells, or neurogenic cell divisions are 
sufficiently different from the somatic cell divisions being differently affected by 
disturbances of ASPM function (Higgins et al., 2010). 
 Simplified gyral pattern, corpus callosum anomalies, cerebellar and/or pontine 
hypoplasia have been reported as the most frequent cerebral anomalies in ASPM-related 
microcephaly (Bond et al., 2002, Bond et al., 2003, Woods et al., 2005, Létard et al., 
2018). In contrast to these findings, our patient showed very severe cortical dysplasia 
with features of polymicrogyria. Our search of the literature revealed only a single patient 
with similar malformation of cortical development in ASPM mutation in addition to 
another patient with unilateral polymicrogyria (Passemard et al., 2009, Létard et al., 
2018). We can hypothesize that modifying factors, still unknown, contributed to the 
development of this serious cortical malformation.  
The human WDR62 gene maps to chromosome 19q13.12, consists of 32 exons 
and encodes a 1523 amino acid protein containing several WD40 repeats (Shohayeb et 
al., 2018). More than 30 pathogenic mutations in WDR62 have already been published. 
The frameshifts, missense, nonsense and splice site mutations in the WDR62 gene are 
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randomly distributed. In addition to microcephaly, a wide range of malformations, 
including pachygyria, cortical thickening, cortical dysplasia, heterotopia, polymicrogyria, 
schizencephaly, dysmorphic hippocampus, corpus callosum abnormalities and cerebellar 
hypoplasia was described in these patients (Shohayeb et al., 2018). Neuropathology in a 
fetus with WDR62 mutation revealed severe disruption of cortical neuronal architecture, 
immature radial columnar organization, and heterotopia in the intermediate zone (Yu et 
al., 2010).  
We found diffuse pachygyria, thickened cortex and indistinct grey-white matter 
junction in our two patients from related families with the same novel homozygous 
missense WDR62 mutation [c.668T>C, p.(Phe223Ser)]. This mutation affects one of the 
WD40 repeat regions of the WDR62 protein. WD40 repeat is a short structural motif of 
approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) 
dipeptide. The common function of all WD40 repeat proteins is coordinating multiprotein 
complex assemblies, where the repeating units serve as a rigid scaffold for protein 
interactions (Li and Roberts, 2001, Stirniman et al., 2010). 
Experimental data on Aspm 
In embryonic mice Aspm protein was highly expressed in the neuroepithelial cells 
when symmetric, proliferative divisions prevailed and declined progressively at later 
stages of neurogenesis (Bond et al., 2002, Fish et al., 2006, Capecchi and Pozner, 2015). 
It was recruited to the pericentriolar matrix at the spindle pole (Fish et al., 2006). Aspm 
by interacting with citron kinase exerted a critical role at the spindle poles of 
neuroepithelial cells in maintaining spindle axis exactly perpendicular to the 
neuroepithelial cell apical-basal axis throughout mitosis and, consequently, in ensuring 
the precise cleavage plane orientation required for symmetric, proliferative divisions 
(Fish et al., 2006, Gai et al., 2016). Loss of Aspm in knockdown mice resulted in 
deviation of spindle position, hence increasing the probability of asymmetric division of 
neuroepithelial cells, causing reduced expansion of neuroepithelial pool and leading to 
primary microcephaly (Fish et al., 2006, Fish et al., 2008, Gai et al., 2016 ).  
Recent investigations revealed that ASPM has a mitotic orientation-independent 
effect on cell cycle duration. Regardless of division orientation, if the G1-phase of the cell 
cycle is sufficiently long for the cell to receive and process intrinsic or extrinsic 
differentiating signals, then the daughter cells will exit the cell cycle. ASPM by 
interaction with the Cdk2/Cyclin E complex regulates numerous aspects of the cell cycle 
progression, including mitosis duration and passage through the G1 restriction point 
20 
 
(Dehay and Kennedy, 2007, Capecchi and Pozner, 2015). Indeed, it has been shown in 
Aspm mutant mice that the cell cycle of the neural progenitor cells was prolonged. 
Especially, significant lengthening of the transition from the early G1 phase of the cell 
cycle to late G1 through the restriction point was observed, presumably promoting 
asymmetric division of the neural progenitor cells (Dehay and Kennedy, 2007, Capecchi 
and Pozner, 2015).  
Experiments in Aspm knockout ferret, a species with a larger gyrified cortex and 
greater neural progenitor cell diversity than mice, basically confirmed a few aspects of 
Aspm function described in mice. A very large premature displacement (delamination) of 
ventricular radial glia cells (a type of neural progenitor cells) to the outer subventricular 
zone was observed in Aspm knockout ferret. Many of these cells resembled outer radial 
glia, a subtype of neural progenitor cells that are essentially absent in mice and have been 
implicated in cerebral cortical expansion in primates. These data suggested that Aspm 
regulates cortical expansion by controlling the affinity of ventricular radial glial cells for 
the ventricular surface, thus modulating the ratio of ventricular radial glial cells, the most 
undifferentiated cell type, to outer radial glia, a more differentiated progenitor (Fish et al., 
2008, Johnson et al., 2018).  
Experimental data on Wdr62 
In vitro tests on cells with WDR62/Wdr62 mutations and in vivo experiments in 
mice with knockdown or genetic inactivation of Wdr62 showed similarities to the 
abnormalities found in patients with ASPM mutations and mice with Aspm knockdown 
(Shohayeb et al., 2018). The regulation and subcellular localization of WDR62 was found 
also to be cell cycle dependent. WDR62 protein accumulated strongly at the spindle poles 
during mitosis and showed cytosolic distribution in the interphase (Yu et al., 2010, 
Nicholas et al., 2010, Bogoyevitch et al., 2012, Farag et al., 2013, Sgourdou et al., 2017). 
Fibroblasts from a patient with homozygous WDR62 mutation, or cells transfected with 
missense and frameshift WDR62 mutations failed to show protein expression at the 
spindle poles (Nicholas et al., 2010, Farag et al., 2013, Sgourdou et al., 2017). In vivo 
experiments showed impaired proliferation of neocortical progenitors, reduced cortical 
thickness and small brain (Bogoyevitch et al., 2012, Chen et al., 2014, Jayaraman et al., 
2016, Sgourdou et al., 2017). Abnormalities in the centriole duplication, spindle pole 
orientation, symmetric/asymmetric division of neural progenitor cells, defects in the 
mitotic progression, and premature delamination were noticed (Bogoyevitch et al., 2012, 
Chen et al., 2014). Increased apoptosis was also suggested as the cause of reduced brain 
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size (Bilgüvar et al., 2010, Nicholas et al., 2010, Yu et al., 2010, Bogoyevitch et al., 2012, 
Farag et al., 2013, Chen et al., 2014, Jayaraman et al., 2016, Sgourdou et al., 2017).  
Recent studies revealed even more details of the premature depletion of progenitor 
cells and mitotic progression defects in mice with truncated Wdr62 transcripts (Wdr62
1-
21/1-21
) (Sgourdou et al., 2017). As discussed above, centrosomes with differently aged 
mother centrioles are differentially inherited by the two daughter cells of asymmetrically 
dividing radial glia progenitors in the developing neocortex. WDR62 loss in mutant 
Wdr62
1-21/1-21
 mice disrupted asymmetric centrosome inheritance: the percentage of 
centrosomes retaining the old mother centriole decreased in the proliferating zones, while 
the percentage of centrosomes with new mother centrioles increased. The opposite was 
found in the cortical plate suggesting abnormal migration and possibly differentiation. 
This disturbed asymmetric centrosome inheritance may lead to impairment of mitotic 
cycle progression, premature depletion of progenitor cells from the ventricular zone, 
neuronal migration delay, altered neuronal differentiation and microcephaly eventually 
(Sgourdou et al., 2017).  
As already mentioned, the Chromosome Passenger Complex is a major regulator 
of mitosis. It has been demonstrated that a fraction of WDR62 protein transiently co-
localizes with Aurora kinase B as well as Survivin during mitosis. WDR62 disruption 
caused a decrease in centromere levels of Aurora B kinase at prophase, and a significant 
increase in levels of survivin at metaphase in fibroblasts from a patient with homozygous 
Asp955AlafsTer112 mutation in WDR62 suggesting perturbed kinetochore function 
(Sgourdou et al., 2017). 
Experimental data on Aspm and Wdr62 interaction 
Aspm and Wdr62 proteins share common localization during the interphase at the 
mother centrioles. It has been shown that Wdr62 is required to localize Aspm and other 
microcephaly–associated proteins to the centrosome. Mouse embryonic fibroblasts 
deficient in Aspm, Wdr62, or both show centriole duplication defects. It seems likely that 
centriole number and organization are critical for progenitor attachment to the ventricular 
surface and the maintenance of neural progenitors. Contrary to previous observations, it 
has been hypothesised recently that centriole duplication defect rather than premature 
asymmetric mitotic spindle orientation might be the major factor leading to depletion of 
progenitor cells resulting in microcephaly (Jayaraman et al., 2016, Jayaraman et al., 
2018). 
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Taken together the experimental data provided some insight into the role of 
Aspm/ASPM and Wdr62/WDR62 function in the development of brain size, however 
failed to clarify the precise mechanism of the wide range of structural abnormalities. 
 
MEGALENCEPHALY 
FOXP1 gene  
FOXP1 (forkhead box protein P1; OMIM 605515) belongs to the functionally 
diverse family of forkhead (FOX) transcription factor proteins. It is one of four members 
of the FOXP subfamily (FOXP1-4) and acts as a transcriptional repressor (Wang et al., 
2003, Golson and Kaestner, 2016). The FOXP1 gene is located on chromosome 3p13 and 
consists of 16 exons coding for a protein with four tissue-specific, alternatively spliced 
isoforms. The FOXP1 protein (Fig. 11 A), in addition to the forkhead/winged helix DNA-
binding domain (FOX), possesses a leucine zipper motif, a zinc finger domain and an N-
terminal polyglutamine (Q-rich) stretch (Wang et al., 2003, Meerschaut et al., 2017). The 
leucine zipper and zinc finger domains promote homodimerization and 
heterodimerization to the other FOXP family members, which is essential for DNA 
binding and transcriptional regulation. The N-terminal polyglutamine tract modulates the 
transcriptional repression activity of FOXP1 (Li et al., 2004). 
Monogenic FOXP1 pathogenic variants (missense, nonsense, splice site 
mutations, deletions, or frameshifts), or more extensive 3p chromosomal deletions 
encompassing FOXP1 have been reported previously in approximately 50 patients. No 
specific genotype-phenotype correlation was found (Hamdan et al., 2010, LeFevre et al., 
2013, Meerschaut et al., 2017). A FOXP1 mutation-related phenotype (OMIM 613670) as 
a recognizable entity has been outlined with intellectual disability, specific language 
impairment with or without autistic spectrum disorder and dysmorphic features (LeFevre 
et al., 2013, Meerschaut et al, 2017). The c.1573C>T, p.(Arg525Ter) heterozygous 
nonsense de novo FOXP1 mutation in our patient causes premature truncation of the 
protein in the winged-helix evolutionally conserved DNA-binding (FOX) domain by 
abolishing the last 152 amino acids of FOXP1. In vitro functional characterization of 
FOXP1 variants provided evidence that this mutation was pathogenic (Sollis et al., 2016, 
Meerschaut et al., 2017). Direct fluorescence imaging studies showed that the wild type 
protein was localized to the nuclei, excluded from the nucleoli, while the p.Arg525Ter 
variant was excluded from the nuclei and formed large cytoplasmic aggregate suggesting 
misfolding of the aberrant protein (Sollis et al., 2016). In addition, the variant lost its 
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transcriptional repressive activity pointing to disturbance of transcription regulation 
(Hamdan et al., 2010, Sollis et al., 2016, Meerschaut et al., 2017). FOXP proteins regulate 
gene expression by forming homo- and hetero-dimers with each other and they interact 
with other transcription factors forming a network involved in cortical development 
(Estruch et al., 2018). Protein interaction studies revealed that the p.Arg525Ter variant 
did not interact with wild type FOXP1/FOXP2 and was unable to self-associate, likely 
because of misfolding (Sollis et al., 2016). In vivo, however, it is possible that the 
nonsense mutation results in nonsense-mediated mRNA decay. 
Experimental data on FOXP1 
The precise functions of FOXP1 transcription factor in brain development 
remained unclear so far. FOXP1/Foxp1 was found to be expressed in the developing 
cerebral cortex in humans and experimental animals following neuronal migration 
suggesting a role for this gene in neuronal differentiation (Ferland et al., 2003, Teramitsu 
et al., 2004). 
Homozygous loss of Foxp1 in all tissues was embryonically lethal in mice 
because of cardiac defect (Wang et al., 2003). Brain specific homozygous Foxp1 deletion 
resulted in viable offspring with postnatal reduction of the dorsal and enlargement of the 
ventral regions of the striatum. These animals displayed reduced excitability in the CA1 
hippocampal pyramidal neurons and showed developmental delay in association with 
impaired behavior (Bacon et al., 2015). It is noteworthy that an increase in the total brain 
volume, or abnormalities of the corpus callosum were not described in these mutant mice. 
Recently, neuronal migration defect with ectopic neurons in deep layers of the cortex 
have been found in mice following down-regulation of Foxp1 expression in the cerebral 
cortex (Li et al, 2015). Migration, or cortical lamination defect were not seen in our 
patient by conventional MRI; however, it could not be excluded at histological level, 
beyond the scope of MRI resolution. Dendritic spine dysgenesis appeared to be a 
common finding in individuals with intellectual disability and autism-related disorders 
[Phillips et al., 2015] and indeed, it might be responsible for the severe intellectual 
disability in our patient.  
PTCH1 gene 
The PTCH1 gene on chromosome 9q22.3 is a human homolog of the Drosophila 
segment polarity gene, patched (patched homolog 1, OMIM 601309; ptc, or Patched1 in 
some of the publications on rodents) and consists of 23 exons (Hahn et al., 1996, 
Lindström et al., 2006). It encodes a transmembrane glycoprotein (Fig. 11 B) composed 
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of 1447 amino acids with 12 transmembrane regions, an intracellular and two 
extracellular loops, and a putative sterol-sensing domain (Hahn et al., 1996, Lindström et 
al., 2006). It functions as a sonic hedgehog (SHH) receptor and regulates SHH signaling 
at the primary cilium (Marigo et al., 1996, Rohatgi et al., 2007, Briscoe and Thérond, 
2013). SHH has an important role in embryonic development by establishing cell fate in 
the neural tube, somites, and limbs. (Briscoe and Thérond, 2013, Jia et al., 2015, 
Pellegrini et al., 2017). In the absence of SHH, PTCH1 represses the function of the 
seven-pass transmembrane protein, Smoothened (SMO). SHH binding to PTCH1 inhibits 
this repression of SMO, which results in the activation of the GLI (Glioblastoma-
associated oncogene) family transcription factors (Rohatgi et al., 2007, Briscoe and 
Thérond, 2013, Gong et al., 2018) (Fig. 11 C).  
Heterozygous germline PTCH1 mutations cause Gorlin syndrome (OMIM 
109400, Gorlin-Goltz syndrome, nevoid basal cell carcinoma, or basal cell nevus 
syndrome), an autosomal dominant disorder that predisposes affected individuals to 
developmental defects and tumorigenesis (Kimonis et al, 1997, Gorlin 2004, Pellegrini et 
al., 2017). Dozens of pathogenic variants in the PTCH1 gene include deletions or 
insertions, (multi)exon or large-scale deletions or rearrangements resulting in frameshifts, 
nonsense mutations leading to premature stops, missense, splice-site mutations, and deep 
intronic variants that alter splicing (Hahn et al., 1996, Lindström et al., 2006, Gianferante 
et al., 2018). A careful analysis revealed that high frequency of mutations is clustered into 
the intracellular and two extracellular loops (Lindström et al., 2006). Indeed, the 
p.(Arg945GlnfsTer22) in our patient affects one of the extracellular loops Fig. 11 B), 
leading to protein truncation, or nonsense-mediated mRNA decay. Either way, the 
attachment of SHH to the receptor PTCH1 and the suppression of SMO by PTCH1 might 
be impaired resulting in dysregulation of the SHH signaling pathway.  
Experimental data on PTCH1 (patched homolog 1) 
 Consistent with the role of Shh in brain development, patched homolog 1 (Ptch1, 
PTCH1) the putative receptor for Shh protein plays also an important role in neural 
development. Experimental studies showed expression of Ptch1 protein throughout the 
mouse embryo. It was bound to Shh and other hedgehog family members and formed a 
complex with Smo (Carpenter et al., 1998). Mice homozygous for the Patched mutation 
(Ptc
-/-
) died during embryogenesis and were found to have open and overgrown neural 
tubes (Goodrich et al., 1997). Mice heterozygous for the Ptc mutation were larger than 
normal, and a subset of them developed hindlimb defects or cerebellar medulloblastoma 
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(Goodrich et al., 1997). These studies suggest that the balance between hedgehog and Ptc 
activities appears critical for normal development and neural fate determination 
(Goodrich et al., 1997). 
The role of PTCH1 in oncogenesis 
Experiments revealed that inactivation of the Ptc gene either in cerebellar granule 
neuron precursors or multipotent neural stem cells led to Shh pathway activation and 
medulloblastoma (Yang et al., 2008). Patients with PTCH1 mutations have high risk of 
medulloblastoma and/or basal cell carcinoma due to SMO activation and increased 
transcription of SHH-pathway target genes (Pellegrini et al., 2017). Medulloblastoma is 
the most common malignant paediatric brain cancer and comprises four major subgroups 
[Sonic hedgehog (SHH), WNT, group 3, and group 4). Proliferation of cerebellar granule 
cell precursors that give rise to SHH-medulloblastoma is regulated by SHH signalling 
during the third trimester to the first few months of life in human. Most of the SHH-
medulloblastoma samples have mutations in four genes that lead to SHH pathway 
activation: loss of function mutations in two genes that inhibit the SHH pathway 
[Patched1 (PTCH1) and SUFU], activating mutations in Smoothened (SMO), and TP53 
loss associated with amplification of GLI2 or NMYC that act downstream of SHH (Tan et 
al., 2018). Interestingly, the lateral cerebellum is preferentially sensitive to high sonic 
hedgehog signalling and 59% of tumours with PTCH1 mutation develop in the cerebellar 
hemispheres (Tan et al., 2018). 
Coexistence of FOXP1 and PTCH1 mutations 
Heterozygous disruptions in both FOXP1 and PTCH1 genes were found in our 
patient with extreme megalencephaly, partial callosal agenesis and profound intellectual 
disability. Common and distinct features described either in FOXP1 or PTCH1 mutations 
could be recognized (Table 2). Several clinical characteristics of Gorlin syndrome, like 
basal cell carcinoma, multiple jaw keratocysts, cardiac and ovarian fibromas were 
lacking, but these features have age-dependent manifestation, and their presence in a child 
would not be expected (Veenstra-Knol et al., 2005, Kimonis et al., 2013). Facial milia and 
skeletal abnormalities were not observed and medulloblastoma did not develop until the 
last follow-up. (Gorlin, 2004, Kimonis et al., 2004, Veenstra-Knol et al., 2005).  
A tendency to head circumference above mean and megalencephaly have been 
described either in FOXP1-, or PTCH1-related conditions, however, such an extreme rate 
of head growth, as seen in our patient has never been reported in association with disease-
causing variants in these genes (Kimonis et al., 1997, Hamdan et al., 2010, LeFevre et al., 
26 
 
2013, Kimonis et al., 2013, Fuji K et al., 2014, Meerschaut et al., 2017). Although 
structural brain abnormalities have been found occasionally in FOXP1-related disorders, 
corpus callosum malformation has not been reported (Meerschaut et al, 2017). Brain 
malformations were also rarely reported in association with PTCH1 mutations: partial or 
complete agenesis of the corpus callosum was found only in a few cases (Kimonis et al., 
1997, Takanashi et al., 2000, Kimonis et al., 2004, Veenstra-Knol et al., 2005, 
Mazzuoccolo et al., 2014, Morita et al., 2015). Recently, however, volumetry has 
revealed reduced callosal thickness in association with enlarged hemispherical and 
cerebellar diameters in children with PTCH1 mutations and nevoid basal cell carcinoma 
(Shiohama et al., 2017). It seems that the intellectual disability and language deficit were 
less severe in children with mutations only in one of these genes (Kimonis et al., 2013, 
Meerschaut et al., 2017). We suggest that the effects of multiple hits, disruptive disease-
causing variants in two different genes simultaneously added and resulted in the serious 
composite clinical phenotype in our patient. FOXP1 mutation might contribute to the 
severe intellectual disability, while the extreme megalencephaly in association with the 
partial callosal agenesis might rather be related to the PTCH1 mutation (Table 2). 
Further studies on possible functional interactions between the two genes may clarify the 
molecular basis of this phenotype. 
Activating mutations in the PI3K (phosphatidylinositol-3-kinase) – AKT (AK mouse 
+ Transforming or Thymoma) -mTOR pathway and megalencephaly.  
 Mutations of upstream (PIK3R2, PIK3CA, PTEN), central (AKT3, TSC1, TSC2, 
MTOR, DEPDC5) and downstream (CCND2) genes within the PI3K-AKT-mTOR 
pathway are associated with brain overgrowth (megalencephaly), as well as cortical 
dysplasia (such as hemimegalencephaly, focal cortical dysplasia and polymicrogyria). 
Mutations in these genes lead to activation of the PI3K-AKT-mTOR pathway (Mirzaa et 
al., 2013, Mirzaa et al., 2016, D’Gama et al., 2017).  
The PI3Ks are members of a unique and highly conserved family of intracellular 
lipid kinases that phosphorylate the 3’-hydroxyl group of phosphatidylinositol and 
phoshoinositides, a reaction that leads to the activation of many complex intracellular 
signalling pathways including the PI3K-AKT-mTOR network. These signalling enzymes 
regulate a wide range of processes, including cell growth, proliferation, survival, 
migration, metabolism, angiogenesis, apoptosis, tumorigenesis and brain development 
(Cohen, 2013, Engelman et al., 2006, Manning and Toker, 2017). 
27 
 
There are three classes (I-III) of PI3Ks according to their substrate preferences and 
sequence homology. Class I PI3Ks are divided into two subfamilies, depending on the 
receptors to which they couple. Class IA PI3Ks are activated by growth factor receptor 
tyrosine kinases (RTKs, Fig. 12), whereas class IB PI3Ks are activated by G-protein-
coupled receptors (Cohen, 2013, Engelman et al., 2006, Fig. 12 B)). Gene mutations, 
described so far as responsible for megalencephaly, affect subunits of class IA PI3Ks. 
Class IA PI3Ks are composed of heterodimers of p110 catalytic and p85 
regulatory subunits (Fig. 12), each of which has several isoforms encoded by three genes. 
Three genes - PIK3CA, PIK3CB, and PIK3CD - encode the highly homologous p110 
catalytic subunit isoforms p110α, p110β, and p110δ, respectively. (Cohen, 2013, 
Engelman et al., 2006). Three genes, PIK3R1, PIK3R2 and PIK3R3 encode the p85α, 
p85β and p55γ isoforms of the p85 regulatory subunit, respectively. The class IA p85 
regulatory isoforms have a common core structure consisting of a p110-binding domain 
flanked by two Src-homology 2 (SH2) domains . The p85 regulatory subunit is crucial in 
mediating the activation of class IA PI3K by receptor tyrosine kinases (RTKs, Cohen, 
2013, Engelman et al., 2006) (Fig 12). 
AKT is the most widely studied effector of PI3K signalling. There are three 
isoforms (Figs. 10 A, 12); AKT1 and AKT2 isoforms are ubiquitously expressed, 
whereas the AKT3 isoform is mainly expressed in the brain and testis. (Cohen, 2013, 
Manning and Toker, 2017). Each of the AKT isoforms contains a pleckstrin homology 
domain (PH, amino acids 5-107 in AKT3) in the N-terminal region followed by the linker 
region (amino acids 107-148 in AKT3) connecting the PH domain to the kinase 
(catalytic) domain (amino acids 148-405 in AKT3) and the regulatory C-terminal region 
(amino acids 406-479 in AKT3) (Figs. 10 A, 12). Pleckstrin is a protein found in platelets 
and its name stands for platelet and leukocyte C kinase substrate and the KSTR string of 
amino acids. (Cohen, 2013, Manning and Toker, 2017). All three AKT isoforms undergo 
membrane recruitment through the N-terminus PH domain which binds to PIP3 and the 
inactive forms of the AKTs become activated by this attachment (Cohen, 2013, Manning 
and Toker 2017) (Fig 12). The chromosomal localization of the three genes encoding the 
AKT isoforms are as follows: AKT1 on chromosome 14q32.3 (OMIM 164730), AKT2 on 
chromosome 19q13.2 (OMIM 164731), and AKT3 on chromosome 1q43-q44 (OMIM 
611223) (Fig 10 A). 
 The activity of the PI3K can be assessed by immunostaining to compare PIP3 
amounts in lymphoblastoid cell lines derived from mutation carriers with megalencephaly 
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to those in controls (Rivière et al., 2012). The activation state of kinases in the PI3K-
AKT-mTOR pathway can be examined through the use of antibodies specific for the 
phosphorylated forms of their target proteins. Phosphorylation of the downstream targets, 
such as ribosomal protein S6 and eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1) reflects the activation at any level of the PI3K-AKT-mTOR pathway 
(Engelman et al., 2006, Lee et al., 2012, Jansen et al., 2015, Biever et al., 2015, Qin et al., 
2016). 
AKT3 gene  
Mutations in AKT3 are responsible for megalencephaly-polymicrogyria-
polydactyly-hydrocephalus syndrome 2; MPPH2, OMIM 615937). AKT3 consists of 24 
exons and 479 amino acids. Mutations of AKT1 and AKT2 have been identified in somatic 
overgrowth disorders such as Proteus syndrome (Lindhurst et al., 2011) and in somatic 
overgrowth with hypoglycaemia (Hussain et al., 2011), respectively.  
At first, copy number changes suggested a role of AKT3 in brain size control. In 
hemimegalencephaly and focal cortical dysplasia mosaic somatic partial 1q trisomy and 
mosaic somatic trisomy of the 1q21.1-q44 chromosomal region were found in surgically 
removed tissue. These regions encompassed the AKT3 gene (Poduri et al., 2012; Conti et 
al., 2015). Germline duplication of 1q43q44 that included AKT3 was associated with 
megalencephaly probably due to dosage imbalance (Wang et al., 2013; Chung et al., 
2014; Hemming et al., 2016). In contrast, microdeletions of 1q43q44 regions were 
associated with microcephaly, suggesting that haploinsufficiency of this gene might be 
responsible for this phenotype (Ballif et al., 2012; Gai et al., 2015; Hemming et al., 2016; 
Depienne et al., 2017). 
Before 2017 a few constitutional mutations of AKT3 in association with 
megalencephaly and polymicrogyria and several mosaic mutations in 
hemimegalencephaly were reported (Riviere et al., 2012; Lee et al., 2012; Jamuar et al., 
2014; Nakamura et al., 2014; Jansen et al., 2015; Harada et al., 2015; Nellist et al., 2015; 
Takagi et al.; 2017; Negishi et al., 2017). Eventually the wide spectrum of developmental 
disorders found in 11 children reported previously and 14 newly diagnosed individuals 
with either constitutional or mosaic mutations in AKT3 have been reviewed (Alcantara D 
et al., 2017). Patients with constitutional mutations have been segregated into three 
groups, such as (i) megalencephaly-polymicrogyria, including our patient, (ii) 
megalencephaly-polymicrogyria with periventricular heterotopia, and finally (iii) 
megalencephaly with no or subtle cortical malformation and autismus spectrum disorder 
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(Nellist et al., 2015; Takagi et al., 2017; Alcantara et al., 2017). Therefore the phenotype 
associated with AKT3 mutations proved to be wider than the megalencephaly-
polymicrogyria-polydactyly-hydrocephalus syndrome 2 as suggested in the OMIM.  
The moderate dilatation of the lateral ventricles in our patient did not require 
surgical intervention. Polydactyly was not observed, just partial syndactyly of the toes. 
Epilepsy with varying severity was described in AKT3 mutations; the seizure disorder was 
mild and easily controlled in our patient. The global developmental delay was severe, 
corresponding to the extended cortical dysgenesis. Patchy capillary vascular 
malformations, hypoglycaemia (Nellist et al., 2015, Alcantara et al., 2017), and growth 
hormone deficiency (Takagi et al., 2017) were reported in association with AKT3 
mutations, however they were absent in our patient.  
The constitutional de novo heterozygous missense variant, c.1393C>T, 
p.(Arg465Trp), found in our patient was published only in 7 individuals (Fig. 10 B) so far 
(Rivière et al., 2012; Jamuar et al., 2014; Alcantara et al., 2017).  It localizes to a CpG 
site in the C-terminal region of AKT3 (Pfeifer, 2006, Rivière et al., 2012,) (Fig 10. A, B).  
Activated AKT phosphorylates downstream substrates either to activate, or more 
often inhibit the function of proteins that are involved in the regulation of diverse cellular 
functions, such as metabolism, translation, proliferation, survival, and angiogenesis 
(Engelman et al., 2006, Cohen, 2013, Manning and Toker 2017). The three best-
established downstream targets of AKT include glycogen synthase kinase 3 (GSK3), 
forkhead box O (FOXO) transcription factors and tuberous sclerosis complex 
2/mammalian target of rapamyicin complex 1 (TSC2/mTORC1). The latter group of 
targets have the most relevance to paediatric neurology. The regulation of cell and tissue 
growth is primarily through the AKT-mediated activation of the protein kinase complex 
mTORC1, which stimulates cell growth. The tuberous sclerosis complex (TSC) a protein 
complex containing TSC1, TSC2 and TBC1D7 is a potent inhibitor of mTORC1. The 
AKT-mediated phosphorylation of TSC2 relieves this inhibition to activate mTORC 
(Engelman et al., 2006, Cohen, 2013, Manning and Toker 2017). 
Experimental data on AKT3 gene 
AKT3 protein is phosphorylated on Thr305 by 3-phosphoinositide-dependent 
protein kinase 1 (PDK1) and on Ser472 by the mTORC2 complex (Fig 12). 
Phosphorylation of AKT at both sites is required for full kinase activity (Manning and 
Toker, 2017). As already mentioned above, phosphorylation of ribosomal protein S6 
serves as a downstream readout of activation at any level of the PI3K-AKT-mTOR 
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pathway. It was demonstrated that cells with the morphology of cytomegalic neurons in 
hemimegalencephaly due to mosaic AKT3 mutation [c.49G>A, p.(Glu17Lys)] were 
strongly labelled for phosphorylated S6, suggesting gain of function in the PI3K-AKT-
mTOR pathway (Lee et al., 2012). Further experiments on surgical brain tissue from 
hemimegalencephaly, - including a specimen with mosaic AKT3 mutation [(c.49G>A, 
p.(Glu17Lys), - and focal cortical dysplasia interestingly exhibited an activation of 
phosphorylation in both the threonine and serine sites of AKT protein regardless of the 
presence or absence of detected PI3K-AKT-mTOR pathway mutations. Patients with 
negative sequencing results either may have mutations of other genes, influencing the 
PI3K-AKT-mTOR pathway, very low level mosaic mutations below the detection limit, 
or aberrant activation of the pathway through other mechanism (Jansen et al., 2015). 
Increased immunosignal was found for antibodies against phosphorylated ribosomal 
protein S6, AKT, its activated, phosphorylated form (pAKT), mTOR, PI3K (p110α), 
PTEN and phosphor-PDK1 also in the brain tissue of a patient with focal cortical 
dysplasia in association with mosaic somatic 1q21.1-q44 duplication, including 
duplication of the AKT3 gene (Conti et al., 2015).  
In other experiments there was no evidence for increased PI3K activity in the 
AKT3-mutant cell line, consistent with a mutation affecting a downstream effector of 
PI3K (Rivière et al., 2012). However, higher S6 and 4E-Bp1 phosphorylation was 
measured in a lymphoblastoid cell line harbouring the AKT3 c.1393C>T; p.(Arg465Trp) 
alteration, strongly suggesting a gain-of-function mechanism resulting in enhanced AKT3 
activity (Rivière et al., 2012; Negishi et al., 2017). Kinase activity analysis also clearly 
showed that all mutations causing megalencephaly, including the constitutional variant, 
found in our patient caused increased activity compared to wild-type, confirming that 
these mutations are also activating the PI3K-AKT-mTOR pathway (Alcantara et al., 
2017).  
In accordance with the microdeletions of the 1q43q44 regions, encompassing the 
AKT3 gene, animal studies revealed that mice lacking Akt3 (Akt3
-/-
) showed 
microcephaly secondary to both a decrease in cell number and reduction in cell size. 
(Easton et al., 2005; Tschopp et al., 2005). In addition ribosomal protein S6 
phosphorylation was decreased by almost 50% in Akt3 knockout brains. It seems that 
Akt3 controls the mass of the mouse brain by influencing both cell size and number, most 
likely through the selective activation of downstream effectors in the PI3K-Akt-mTOR 
pathway (Easton et al., 2005). Seizures were not observed in these animals. On the 
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contrary, heterozygous, or homozygous missense mutation in mice leading to an amino 
acid substitution of aspartic acid to valine (Asp219Val) resulted in seizure susceptibility 
by decreasing the seizure threshold. An increased brain size, ectopic hippocampal 
neurons and enhanced kinase function of AKT3 were also observed in these animals. 
(Tokuda et al., 2011). Our patient with an activating mutation in AKT3 also showed 
susceptibility to seizures, although the polymicrogyria itself may have intrinsic 
epileptogenicity (Kobayashi et al., 2005). 
The PI3K–AKT-mTOR pathway in oncogenesis 
The PI3K-AKT-mTOR pathway is one of the most commonly dysregulated 
pathways in all of cancer. Overexpression and/or mutations of genes encoding the 
tyrosine kinase receptors, or genes of the PI3K pathway represent some of the most 
common mutations in oncology (Cheung and Testa, 2013; Mundi et al., 2016). AKT3 
upregulation due to increased copy number of chromosomal region 1q44, where AKT3 is 
located, was found in hepatitis C virus-associated hepatocellular carcinoma. Moreover 
40-60% of primary melanomas were found to have increased total or phosphorylated 
AKT3 protein compared to normal melanocytes (Stahl et al., 2004; Cheung and Testa, 
2013). AKT plays an important role in the maintenance of the homeostatic balance of cell 
division and growth on one hand, and programmed cell death on the other. Disruption of 
this balance may be responsible for tumorigenesis. The well characterized interactions of 
AKT make it a highly attractive target for cancer therapy (Cheung and Testa, 2013; 
Mundi et al., 2016). Considering the findings regarding the relationship between PI3K-
AKT-mTOR pathway activation and oncogenesis careful monitoring of Patient 5 for 
cancer is warranted.  
 
CONCLUSIONS 
 This study provides phenotypic and genotypic characterization of three patients 
with microcephaly and two patients with megalencephaly. Next generation sequencing 
revealed novel homozygous pathogenic variants in the ASPM and WDR62 genes causing 
autosomal recessive primary microcephaly (MCPH).  These mutations might lead to 
abnormal function of the centrosomes, which organize the separation of chromosome 
copies during cell division. Coexistence of heterozygous de novo variants  in FOXP1 and 
PTCH1 genes was found in association with extreme megalencephaly and profound 
intellectual disability, as a composite phenotype, sharing some features of Gorlin 
syndrome. Activating heterozygous mutation in AKT3, a gene  encoding a protein in the 
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PI3K-AKT-mTOR pathway resulted in megalencephaly and polymicrogyria. There is 
evidence that abnormalities in the PTCH1-SHH and PI3K-AKT-mTOR pathway have 
significant role in oncogenesis, therefore our patients with brain overgrowth require 
regular medical follow-up. Autosomal recessive primary microcephaly and 
megalencephaly are rare diseases and our study is in line with the international efforts of 
discovering the molecular background of these disorders.      
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TABLES 
 
Table 1 
Genes and mutations reported in this study 
  
Patients Genes Exons Nucleotide 
variation 
Amino acid 
variation 
Mutation 
type 
Zygosity Main 
phenotypic 
feature 
Comments 
1 ASPM Exon 18 c.7323T>A p.Tyr2441Ter Nonsense Homozygous Microcephaly Novel 
2 WDR62 Exon 6 c.668T>C p.Phe223Ser Missense Homozygous Microcephaly Novel 
3 WDR62 Exon 6 c.668T>C p.Phe223Ser Missense Homozygous Microcephaly Novel 
4 FOXP1 
PTCH1 
Exon 18 
Exon 17 
c.1573C>T 
c.2834delG 
insAGATGTTGT
GGACCC 
p.Arg525Ter 
p.Arg945Glnfs 
Ter22 
Nonsense 
Frameshift 
Heterozygous 
de novo 
Heterozygous 
de novo 
 
Megalencephaly 
Published 
Novel 
 
5 AKT3 Exon 13 c.1393C>T p.Arg465Trp Missense Heterozygous 
de novo 
Megalencephaly Published 
 
 
 
 
Table 2  
Common versus distinct clinical features attributable to mutations in FOXP1 and PTCH1 
 
 FOXP1 
 (Le Fevre et al., 2013 
Meerschaut et al., 2017) 
PTCH1 
(Veenstra-Knol et al., 2005 
Kimonis et al.,2013 
Shiohama et al, 2017) 
 
Head size Megalencephaly 
Dysmorphic features Prominent forehead 
Strabismus 
Broad nasal bridge 
Frontal hair upsweep 
Down slanting palpebral fissures 
Short nose with broad tip 
Long philtrum 
Abnormally modelled ears 
Highly arched eyebrows 
Low-set ears 
Symmetrical post-axial cutaneous 
appendages (skin tags) on both hands 
 
Brain imaging  Partial agenesis of the corpus callosum 
Widely separated leaves of the septum 
pellucidum 
Enlarged cerebral ventricles 
Neurological signs Global developmental delay 
Profound intellectual disability 
Generalized hypotonia 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Explanatory figure 1 
Centrosome regulation of neural progenitor proliferation 
(A) Alignment of mitotic spindles parallel to the neuroepithelium within the progenitor 
cells results in symmetrical divisions and thereby an increase of the progenitor pool.   
(B and C) An alignment of the spindle perpendicular to the neuroepithelium results in 
asymmetric cell divisions, which maintain the progenitor pool cell numbers while 
producing precursors of various cell types, such as neurons and glial cells.    
(Megraw L, Sharkey JT, Nowakowski RS. Trends Cell Biol 2011;21:470-480) 
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Explanatory figure 2 
Neurons and glial cells further differentiate, mature and migrate.   
(Kaindl AM et al. Prog Neurobiol 2010;90:363-383)  
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Explanatory figure 3  
(A) The cell cycle of eukaryotic cells can be divided into four successive phases: M phase 
(mitosis), S phase (DNA synthesis) and two gap phases, G1 and G2. Centrosomes play an 
essential role in cell division, as they are responsible for the formation and maintenance 
of the microtubule-based spindle apparatus. The centrosome contains a pair of cylindrical 
centrioles in an orthogonal configuration. Centriole duplication occurs during each cell-
cycle and both centrioles and centrosomes undergo final maturation in the G2 and M 
phases. (Prosser SL Pelletier L. Nat Rev Mol Cell Biol 2017;18:187-201, Nigg EA, 
Holland AJ.  Nat Rev Mol Cell Biol 2018;19:297-312, Alcantara D, O’Driscoll M, Am J 
Med Gen Part C Semin Med Genet 2014;166C:124–139) 
(B) Centrosomal duplication results in the generation of a bipolar mitotic spindle.  
(Alcantara D, O’Driscoll M, Am J Med Gen Part C Semin Med Genet 2014;166C:124–
139) 
(C) Centrosome duplication in dividing neuroprogenitors generates a pair of centrosomes 
with differently aged mother centrioles. During peak phases of neurogenesis the 
centrosome retaining the old mother centriole stays in the ventricular zone and is 
preferentially inherited by neuroprogenitors, whereas the centrosome containing the new 
mother centriole mostly leaves the ventricular zone and is largely associated with 
differentiating cells. (Wang et al. Nature 2009;461:947-955) 
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Explanatory figure 4  
The distribution of genetic defects underlying congenital microcephaly attributable to the 
centrosome, spindle and kinetochore. The upper panel depicts a normal bipolar mitosis.  
 In embryonic mice, Aspm protein was recruited to the pericentriolar matrix at the 
spindle pole. It ensured the precise cleavage plane orientation required for symmetric, 
proliferative divisions. Loss of Aspm resulted in deviation of spindle position, hence 
increasing the probability of asymmetric division of neuroepithelial cells, causing reduced 
expansion of neuroepithelial pool and leading to primary microcephaly.  
 WDR62 protein accumulated at the spindle poles during mitosis. Cells with 
WDR62 mutations failed to show protein expression at the spindle poles. Abnormalities in 
the centriole duplication, spindle pole orientation, symmetric/asymmetric division of the 
neuronal progenitor cells, defects in the mitotic progression, and premature delamination 
were noticed.  
  Experiments revealed that Aspm and Wdr62 proteins share common localization 
during the interphase at the mother centrioles. Wdr62 is required to localize Aspm and 
other microcephaly-associated proteins to the centrosome. Mouse embryonic fibroblasts 
deficient in Aspm, Wdr62 or both show centriole duplication defects. It seems likely that 
centriole number and organization are critical for neuronal progenitor attachment to the 
ventricular surface and the maintenance of neuronal progenitors. The centriole 
duplication defect might be the major factor leading to depletion of progenitor cells 
resulting in microcephaly. (Alcantara D. et al. Am J Med Genet 2014;166C:124-139) 
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Fig. 1 
Patient 1. Brain MRI. T2 weighted axial (A), parasagittal (B) and coronal (C) images at 
age of 7 months. The architecture of the cortex is abnormal, features of dysplasia and 
polymicrogyria can be seen. The grey-white matter junction appears indistinct at some 
areas. The Virchow-Robin spaces and lateral ventricles are dilated.  
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Fig. 2.  
Patient 1. Sanger sequencing of part of exon 18 of the ASPM gene shows the homozgous 
T to A mutation at position 7323 of the coding DNA sequence (A). This variant creates a 
premature stop codon. The mutation is heterozygous in the parents (B). The 7323 
positions are indicated by arrows. A normal sequence is also shown in an unrelated 
control subject. (C).  
 
 
  
A 
 
 
 
B 
C 
c. 7323A/A  p.Tyr2441STOP 
 
 
c. 7323T/T 
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Fig. 3  
Pedigree of Patient 2 (A) and Patient 3 (B). Sanger sequencing of part of exon 6 of the 
WDR62 gene shows the homozygous T to C mutation at position 668 of the coding DNA 
sequence (C, arrows). The mutation is heterozygous in the parents and brother of Patient 
1. A normal sequence is also shown in an unrelated control subject (C). The mutation 
affects one of the WD40 repeats in the WDR62 protein (D).   
 
 
 
Homozygous normal DNA sequence 
c.668C/C 
c.668T/T 
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Fig. 4 
MRI of Patient 2 (A, B) at the age of 5 months and Patient 3 (C, D) at the age of 4 years. 
The T2-weighted axial images demonstrate hemispherical asymmetry, diffuse pachygyria 
with a few broad gyri and shallow sulci, wide gray matter, and indistinct white-grey 
matter border in certain areas. The white matter is thin and the ventricles are 
asymmetrically enlarged,. The Virchow-Robin spaces are dilated.   
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Fig. 5 
Haplotype analysis of the families of Patient 2 (A) and 3 (B). Except the 
19.36558314T>C unique variant, all the other examined SNPs are listed by their 
reference numbers. The identical haplotypes are coloured matched. The haplotype linked 
with the causative mutation is coloured magenta. 
SNP: single-nucleotide polymorphism    
 
 
 
 
 
  
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6  
Patient 4. Photographs, head circumference chart and brain MR images.  
(A and B) The patient at the age of 2 (A) and 6 (B) years. Note prominent forehead, 
arched eyebrows, strabismus, flat, wide nasal bridge, short nose with a broad tip, long 
philtrum, small lower jaw and low-set ears with abnormally modelled helices. 
(C) The chart shows the progressive growth of the head circumference. 
(D) Bilateral skin tags on the fifth fingers. 
(E) Sagittal T1-weighted MR image at the age of 3 months shows the partial agenesis of 
the corpus callosum with a thin remnant of the anterior part of the body (arrow). 
(F) Axial T2-weighted MR image at the age of 4 years demonstrates the anterior part of 
the corpus callosum, dilated ventricles and widely separated leaves (arrows) of the 
septum pellucidum.  
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Fig. 7 
Patient 4. FOXP1 mutation.  
(A) Mutation in FOXP1 gene at c.1573 position results in a STOP codon. The mutation is 
very likely de novo since it was absent in the parents. 
(B) The mutated position is highlighted in the DNA sequence of the affected child. 
Y=T/C 
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Fig. 8 
Patient 4. PTCH1 mutation. 
(A) The complex PTCH1 variant caused by a single-nucleotide deletion and a 15 bp long 
insertion in exon 17 which causes a premature STOP codon (p.Arg945GlnfsTer22).  The 
mutated portion of the sequence is highlighted in red. The mutation is very likely de novo 
since it was absent in the parents.  
(B) The presence of PTCH1 mutation at DNA level confirmed by Sanger sequencing in 
the affected child. It is absent in the parents. The complex mutation starts after the 
highlighted portion of the sequence (blue). 
(C) The sequence alignment of the reference and mutated PTCH1 alleles.  
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 
Patient 5. MR images at the age of 7 months. 
T2-weighted axial (A-C), T1-weighted coronal (D-F), T1-weighted parasagittal (G-H) 
and midsagittal (I) images reveal bilateral moderate dilatation of the lateral ventricles and 
wide Sylvian fissures. The extra-axial spaces are also slightly enlarged. Irregular small 
gyri with cortical thickening compatible with polymicrogyria can be seen bilaterally in 
the perisylvian, frontal, parietal and temporal areas with indistinct margin between the 
grey and white matter. The thick corpus callosum shows an abnormal shape. Wide cavum 
septi pellucidi and dilated Virchow-Robin spaces can also be observed.    
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Fig. 10 
(A) Domain structure of AKT isoforms. AKT3 contains 479 amino acids. Each of the 
AKT isoforms contains a pleckstrin homology (PH) domain in the N-terminal region 
followed by a linker region connecting the PH domain to the kinase (catalytic) domain 
and a regulatory C-terminal region (RD). The constitutional heterozygous missense 
variant of AKT3 (c.1393C>T) in Patient 5 leads to a change of arginine into tryptophan at 
the position 465 in the regulatory C-terminal region (arrow) of the AKT3 protein, causing 
activation of the AKT-pathway. (Figure and legend after Cohen, 2013). 
(B) Mutations identified in AKT3 until April 2017 are shown, including Patient 5 in this 
study, along with the numbers of patients with these mutations in brackets. 
DMEG: dysplastic megalencephaly, HET: heterotopia, HMEG: hemimegalencephaly, 
MEG: megalencephaly, PMG: polymicrogyria 
(Alcantara D, Timms AE, Gripp K, Baker L, Park K, Collins S, et al. Mutations of AKT3 
are associated with a wide spectrum of developmental disorders including extreme 
megalencephaly. Brain 2017;140:2610-2622). 
 RD PH Catalytic Domain AKT1 14q32.3 
Thr308 Ser473 
 RD PH Catalytic Domain AKT2 19q13.2 
Thr309 Ser474 
 RD PH Catalytic Domain AKT3 1q43-q44 
Thr305 Ser472 
p.Arg465Trp 
A 
B •   DMEG/HMEG (mosaic, affected tissues only) 
•   MEG-PMG, MEG-HET, MEG (constitutional) 
AKT3  PH Kinase C-ter 
5 107 148 405 479 
p.Val268Ala (x1) 
p.Asn229Ser (x4) 
p.Val183Asp (x2) p.Asp322Asn (x2) p.Arg465Trp (x7) 
p.Trp79Cys (x1) 
p.Asn53Lys (x1) 
p.Phe54Tyr (x1) 
p.Glu40Lys (x1) 
p.Glu17Lys (x5) 
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Fig. 11 
FOXP1 protein. PTCH1 protein and SHH signallig. 
(A) The FOXP1 protein is 677 amino acid long and its major domains are: a glutamine 
rich region (Q-rich), zinc finger (ZF) leucine zipper (LZ) and forkhead box  (FOX) 
domains, and two nuclear localization signals (NLS1 and NLS2). The de novo 
heterozygous Arg525Ter change in Patient 1 is located in the FOX domain (arrow).  
(B) The PTCH1 protein (Hedgehog receptor) consists of 1447 amino acids with 12 
transmembrane regions, an intracellular and two extracellular loops. The de novo 
heterozygous Arg945GlnfsTer22 mutation in Patient 4 is located to one of the 
extracellular loops (arrow), presumably leading to protein truncation, or nonsense-
mediated mRNA decay.  
(C) Hedgehog (HH) signalling. In the absence of HH ligand, the HH receptor PTCH1 is 
enriched in cilia and the seven-transmembrane Smoothened (SMO) is excluded from cilia 
and maintained into an inactive conformation. The GLI (Glioblastoma (GLI) transcription 
factors (GLI2 and GLI3) enter cilia in complex with their partner and inhibitor SUFU 
(Suppressor of Fused) and become processed into transcriptional repressors (Gli
R
) either 
inside cilia or after exit from the cilia. In the presence of HH ligand, PTCH1 disappears 
from the cilium and SMO accumulates in cilia in an active conformation. Active SMO 
prevents the processing of GLI into GLI
R
 and promotes the formation of the 
transcriptional activator form of GLI (GLI
A
). (Figure and legend after Nachury, 2014)  
A 
 
p.Arg525Ter 
 
                                                                                                                                   
 
Q-rich 
 
ZF 
 
LZ 
 
FOX 
  
 
 
NLS1 
 
NLS2 
 
C 
 
PTCH1 
 
SMO 
 
SUFU 
 
GLI 
 
- Hedgehog 
 
+ Hedgehog 
 
HH 
 
GLIᴿ 
 GLIᴬ 
 
HH target gene 
 
 
 
B 
 
Extracellular 
 
Intracellular 
 
N-term 
 
C-term 
 
 
 
p.Arg945Glnfs
Ter22 
 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12 
Schematic illustration of the PI3K-AKT-mTOR pathway. 
Class IA PI3K (Ptdins (3) K on the figure) is a heterodimer that consists of a p85 
regulatory subunit and a p110 catalytic subunit. The regulatory subunit p85 binds to 
phospho-tyrosine residues on activated receptor tyrosine kinases. This binding both 
relieves the basal inhibition of p110 by p85 and recruits the p85-p110 heterodimer to its 
substrate phosphatidylinositol-4,5-bisphosphate [Ptdins (4,5) P2, or PIP2] at the plasma 
membrane leading to the synthesis of phosphatidylinositol-3,4,5-triphosphate [Ptdins 
(3,4,5) P3, or PIP3]. PTEN (phosphatase and tensin homologue) dephosphorylates PIP3 
and therefore terminates PI3K (Ptdins (3) K) signalling. The three isoforms of AKT are 
the most widely studied effectors of PI3K signalling. AKT undergoes membrane 
recruitment binding to Ptdins (3,4,5)P3 (PIP3) and the inactive forms of the AKT become 
activated by this attachment. This process of activation involves phosphorylation of 
threonine in the kinase domain of AKT by phosphoinositide-dependent protein kinase 1 
(PDK1) and phosphorylation of serine in the regulatory domain of AKT by mammalian 
target of rapamycin complex 2 (mTORC2). Following such activation, the inactive AKT 
form is re-established through the action of protein phosphatases. The Thr residues are 
dephosphorylated by phosphatase 2A (PP2A), while the Ser residue of AKT3 is targeted 
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by the isoform 1 of the pleckstrin homology domain leucine-rich repeat protein 
phosphatases (PHLPP1 and PHLPP2). Downstream effects of AKT activation include 
cell growth, proliferation, survival, apoptosis, migration, metabolism and several other 
functions. (Figure and legend after Cohen, 2013) 
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